Summary & Overview
HCPCS Q5128: Ranibizumab-eqrn (Cimerli) Injection, 0.1 mg
HCPCS Level II code Q5128 designates the biosimilar ranibizumab-eqrn (Cimerli), 0.1 mg, for intravitreal injection. This code matters nationally as biosimilar retinal biologics expand treatment options for retinal vascular diseases and age-related macular degeneration, potentially affecting access, utilization, and payer coverage strategies across commercial and public plans. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of clinical context for intravitreal ranibizumab biosimilars, typical sites of service (ophthalmology clinics, ambulatory surgery centers, hospital outpatient departments), and the implications for billing workflows. The publication covers benchmarks for coverage and reimbursement patterns, payer policy considerations, common billing modifiers and coding practice notes, and areas where policy updates may influence provider billing and payer adjudication. Where input data are incomplete, the text notes missing items as "Data not available in the input." The goal is to provide clinicians, billing professionals, and policy analysts a clear, national-level brief on coding and operational considerations tied to Q5128 without making clinical recommendations.
Billing Code Overview
HCPCS Level II code Q5128 represents injection, ranibizumab-eqrn (Cimerli), biosimilar, 0.1 mg. This code is used to report administration of the biosimilar formulation of ranibizumab for intravitreal injection in ophthalmic care.
Service type: Intravitreal biologic injection
Typical site of service: Ophthalmology clinic, ambulatory surgery center, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A 72-year-old patient with neovascular (wet) age-related macular degeneration presents to the ophthalmology clinic with decreased central vision and new subretinal fluid on optical coherence tomography. The retina specialist assesses visual acuity, performs a slit-lamp and dilated fundus exam, and documents the need for an intravitreal anti-VEGF injection. The medication selected is the ranibizumab biosimilar Q5128 (ranibizumab-eqrn, cimerli) dosed per product labeling as an intravitreal injection of 0.1 mg. The clinic verifies informed consent, reviews allergy history, confirms laterality, and performs topical anesthesia and povidone-iodine prep. A sterile field is established in a procedure room within the ambulatory surgical center or office-based ophthalmology suite. After injection, the provider monitors the patient for immediate adverse events, documents the procedure including drug, dose, lot number, and laterality, and provides post-procedure instructions. Follow-up visits include IOP check and retinal imaging to guide further injections.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default (no modifier) | Use when no modifier applies to the service. |
22 |